Bordetella Vaccine for Dogs: Who Needs It and What It Prevents

The Bordetella vaccine for dogs is a noncore (risk-based) immunisation that targets Bordetella bronchiseptica, a primary bacterial agent involved in canine infectious respiratory disease complex (CIRDC), commonly called kennel cough. This vaccine does not prevent all causes of respiratory infection, nor does it guarantee complete protection. Its use is guided by a dog's specific exposure risk, lifestyle, and facility requirements such as boarding kennels, daycare centres, and grooming salons.

This article provides a definitive, evidence-based explanation of the Bordetella vaccine, including who needs it, what it can and cannot do, timing considerations before boarding, and the scientific limits of respiratory-complex prevention. It is written for veterinary professionals, pet owners, and anyone involved in canine care.

At a Glance: Bordetella Vaccine Decision Guide

What Is the Bordetella Vaccine?

The Bordetella vaccine is a biological preparation that stimulates a dog's immune system to produce antibodies against Bordetella bronchiseptica, a Gram-negative bacterium that colonises the ciliated epithelium of the respiratory tract [2]. This bacterium is a primary pathogen in dogs and cats and is one of several infectious agents that contribute to CIRDC.

The vaccine is available in several formulations:

• Intranasal (IN): A modified-live vaccine administered as drops or spray into one nostril. It stimulates local mucosal immunity in the respiratory tract, which is the first line of defence.
• Injectable: A killed (inactivated) or modified-live vaccine given subcutaneously. It produces systemic immunity but may not generate as strong a local mucosal response as the intranasal route.
• Oral: A less common modified-live formulation given orally.

The intranasal route is often preferred because it induces both local secretory IgA antibodies and systemic immunity, providing more rapid protection at the portal of entry. According to the AAHA Canine Vaccination Guidelines, the intranasal Bordetella vaccine can provide protection within 3 to 5 days, making it suitable for last-minute boarding requirements [3].

Who Needs the Bordetella Vaccine? Risk-Based Decision Making

The Bordetella vaccine is classified as a noncore vaccine by major veterinary organisations, including the American Animal Hospital Association (AAHA), the World Small Animal Veterinary Association (WSAVA), and the European StIKo Vet guidelines [1][3][4]. Noncore vaccines are not recommended for every dog. Instead, they are advised based on an individual dog's risk of exposure.

Dogs with High Exposure Risk

The following dogs should receive the Bordetella vaccine:

• Dogs that board at kennels: Boarding facilities typically require proof of Bordetella vaccination, often within the past 6 to 12 months. This is because kennels concentrate many dogs from different households in close quarters, creating ideal conditions for pathogen transmission.
• Dogs that attend daycare: Similar to boarding, daycare centres have high dog-to-dog contact.
• Dogs that visit grooming salons: Grooming involves handling, shared equipment, and potential aerosol exposure.
• Dogs that participate in group training classes: Obedience, agility, and other group classes bring dogs together in enclosed spaces.
• Dogs that attend dog shows, trials, or competitions: These events draw dogs from wide geographic areas, increasing the risk of encountering novel pathogens.
• Dogs that frequent dog parks: Off-leash parks involve direct contact with unfamiliar dogs.
• Dogs that are walked in high-traffic urban areas: Sidewalks, elevators, and waiting rooms can harbour respiratory pathogens.
• Dogs that are housed in shelters or rescue facilities: These environments have high turnover and stress, both of which increase disease transmission.

Dogs with Low Exposure Risk

Dogs that live exclusively indoors, have no contact with other dogs outside their household, and do not visit boarding, daycare, or grooming facilities may not need the Bordetella vaccine. However, even low-risk dogs can be exposed if they encounter a coughing dog on a walk or in a veterinary waiting room. The decision should be made in consultation with a veterinarian.

Puppies and Senior Dogs

Puppies are at higher risk for severe respiratory disease because their immune systems are immature. The StIKo Vet guidelines emphasise that basic immunisation in puppies is critical for long-term health [1]. For puppies that will be socialised or boarded, the Bordetella vaccine can be given as early as 6 to 8 weeks of age, depending on the product label.

Senior dogs with underlying health conditions (e.g., chronic bronchitis, heart disease, or immunosuppression) may also benefit from vaccination if they have exposure risk, but the decision must weigh the potential for adverse effects against the risk of infection.

What Does the Bordetella Vaccine Prevent?

The Bordetella vaccine specifically targets Bordetella bronchiseptica infection. It does not prevent all causes of kennel cough.

The Canine Infectious Respiratory Disease Complex (CIRDC)

CIRDC, commonly called kennel cough, is a multifactorial syndrome caused by a combination of viral and bacterial pathogens. The most common agents include:

• Bacteria: Bordetella bronchiseptica, Mycoplasma species, Streptococcus equi subsp. zooepidemicus
• Viruses: Canine parainfluenza virus (CPiV), canine adenovirus type 2 (CAV-2), canine distemper virus (CDV), canine respiratory coronavirus, canine influenza virus (H3N8 and H3N2), and others

The Bordetella vaccine only covers the bacterial component. A dog vaccinated against Bordetella can still contract kennel cough from any of the viral agents. For this reason, many veterinarians recommend combination vaccines that include canine parainfluenza and canine adenovirus type 2, which are core or recommended components in many guidelines [1][3].

Limits of Protection

No vaccine provides 100% protection. The Bordetella vaccine reduces the severity and duration of clinical signs but does not prevent infection entirely. Vaccinated dogs can still become infected with Bordetella bronchiseptica, shed the bacterium, and transmit it to other dogs. This is especially true if the dog is exposed to a high infectious dose or if the vaccine is not administered according to the recommended schedule.

According to the AAHA guidelines, the intranasal vaccine provides more rapid and localised immunity than the injectable form, but breakthrough infections can still occur [3].

Timing Before Boarding: Facility-Specific Requirements

One of the most common questions from dog owners is: "How far in advance does my dog need the Bordetella vaccine before boarding?"

The answer depends on the vaccine formulation and the specific facility's policy.

Intranasal Vaccine

• Onset of immunity: 3 to 5 days
• Typical facility requirement: 7 to 14 days before boarding
• Duration of immunity: Approximately 12 months, though some facilities require a booster every 6 months

The intranasal vaccine is ideal for last-minute boarding because it works quickly. However, some facilities still require a minimum interval of 7 days to ensure the dog does not develop vaccine-related side effects (e.g., mild coughing or sneezing) that could be mistaken for illness.

Injectable Vaccine

• Onset of immunity: 2 to 4 weeks (requires a booster 2 to 4 weeks after the first dose for initial immunisation)
• Typical facility requirement: 2 to 4 weeks before boarding
• Duration of immunity: 12 months

The injectable vaccine takes longer to induce protective immunity, so it is less suitable for last-minute planning.

Oral Vaccine

• Onset of immunity: Similar to intranasal, approximately 5 to 7 days
• Typical facility requirement: 7 to 14 days before boarding

Facility Policies Vary

Each boarding kennel, daycare, or grooming facility sets its own vaccination requirements. Some accept any form of Bordetella vaccine given within the past 12 months. Others require the intranasal form specifically. Some facilities require a booster every 6 months, especially during peak respiratory disease seasons.

Owners should always confirm the specific requirements with the facility before scheduling vaccination. It is also wise to carry a copy of the vaccination record.

How the Bordetella Vaccine Works: Immunology and Administration

Mechanism of Action

Bordetella bronchiseptica colonises the ciliated epithelial cells lining the respiratory tract. It produces toxins that paralyse cilia, allowing the bacterium to adhere and multiply. The immune system responds by producing antibodies, particularly secretory IgA at the mucosal surface, which prevent bacterial adherence and neutralise toxins.

The intranasal vaccine delivers a modified-live bacterium directly to the nasal mucosa. This stimulates a strong local IgA response, as well as systemic IgG and cell-mediated immunity. The injectable vaccine, being killed or modified-live but given systemically, induces primarily systemic immunity with less local mucosal protection.

Administration Routes

• Intranasal: The vaccine is administered as a single dose (0.5 mL or 1 mL, depending on product) into one nostril. The dog may sneeze or cough immediately after administration, which is normal. Some product labels recommend dividing the dose between both nostrils.
• Injectable: Given subcutaneously in the scruff of the neck or over the shoulder. A booster is required 2 to 4 weeks after the first dose for initial immunisation in puppies or naive adults.
• Oral: Given as a liquid in the mouth. This route is less common but available in some markets.

Adverse Effects

Most dogs tolerate the Bordetella vaccine well. Potential adverse effects include:

• Mild coughing, sneezing, or nasal discharge (especially with intranasal vaccines)
• Lethargy or decreased appetite for 24 to 48 hours
• Injection site discomfort (with injectable vaccines)
• Rare allergic reactions (urticaria, facial swelling, vomiting, diarrhoea, or anaphylaxis)

Serious adverse events are uncommon. Owners should report any concerning signs to their veterinarian.

Why the Bordetella Vaccine Is Not a Core Vaccine

Core vaccines are those recommended for all dogs regardless of lifestyle because they protect against severe, widespread, or zoonotic diseases. The core vaccines for dogs, according to the StIKo Vet guidelines, are distemper, parvovirosis, and leptospirosis [1]. The AAHA and WSAVA also classify canine adenovirus type 2 (which protects against hepatitis) as core.

The Bordetella vaccine is noncore for several reasons:

1. Disease severity: Kennel cough is usually self-limiting and rarely life-threatening in otherwise healthy adult dogs. Severe pneumonia can occur in puppies, seniors, or immunocompromised dogs, but this is not the norm.
2. Limited spectrum: The vaccine only covers one of many pathogens in CIRDC. Vaccination does not eliminate the risk of respiratory disease.
3. Variable exposure: Many dogs live in low-risk environments and may never encounter Bordetella bronchiseptica.
4. Short duration of immunity: Protection may wane within 6 to 12 months, requiring frequent boosters that are not justified for low-risk dogs.

The noncore classification does not mean the vaccine is unimportant. For dogs with high exposure risk, it is a valuable tool for reducing morbidity.

Regional Variations and Guidelines

Vaccination recommendations vary by region due to differences in disease prevalence, regulatory approvals, and veterinary practice standards.

United States and Canada

The AAHA Canine Vaccination Guidelines (2022) classify the Bordetella vaccine as noncore but strongly recommend it for dogs that are socially active [3][4]. The AVMA supports risk-based decision making. In Canada, the CVMA similarly recommends Bordetella vaccination based on exposure risk.

Europe

The StIKo Vet guidelines from Germany classify Bordetella as a noncore vaccine [1]. Many European countries have licensed intranasal and injectable products. The European ABCD guidelines for cats also note that Bordetella bronchiseptica can infect cats and that dogs with respiratory disease pose a risk to cats [2]. This cross-species transmission is an important consideration in multi-pet households.

Australia

The AVA and DAFF support risk-based vaccination. Bordetella vaccination is common in boarding and daycare settings. Australian veterinarians often recommend the intranasal vaccine for its rapid onset.

United Kingdom

The FVE and individual UK veterinary bodies follow similar risk-based approaches. Bordetella vaccination is widely used in kennels and rescue centres.

The Role of the Bordetella Vaccine in Multi-Pet Households

Bordetella bronchiseptica can infect both dogs and cats [2]. In households with both species, a dog with respiratory disease can transmit the bacterium to cats, and vice versa. The ABCD guidelines for cats note that cats with B. bronchiseptica infection can develop mild to severe respiratory signs, including pneumonia and death [2].

Vaccinating a dog against Bordetella may reduce the risk of transmission to feline housemates, especially if any cats are young, old, or immunocompromised. However, the vaccine does not eliminate shedding entirely, so other preventive measures (e.g., isolating sick animals, good hygiene) remain important.

Diagnostic Considerations for Respiratory Disease

When a dog presents with coughing, it is important to determine the cause. Bordetella bronchiseptica is only one possibility. Diagnostic options include:

• History and clinical signs: A harsh, honking cough that is worse with excitement or exercise is classic for kennel cough. Fever, nasal discharge, and lethargy may be present.
• Bacterial culture: Samples from the oropharynx or transtracheal wash can be cultured for Bordetella. However, sensitivity is limited [2].
• PCR testing: Polymerase chain reaction (PCR) can detect Bordetella DNA from nasal or pharyngeal swabs. Sensitivity is higher than culture but not perfect [2].
• Radiography: Thoracic radiographs may be indicated if pneumonia is suspected.

Treatment for confirmed Bordetella bronchiseptica infection typically involves antibiotics. Doxycycline is the antimicrobial of choice [2]. Supportive care, including rest, hydration, and nutritional support, is also important.

Prevention Beyond Vaccination

Vaccination is one component of a comprehensive respiratory disease prevention plan. Other measures include:

• Good ventilation: Kennels and daycare facilities should have adequate airflow to reduce aerosolised pathogens.
• Disinfection: Bordetella bronchiseptica is susceptible to common disinfectants [2]. Regular cleaning of surfaces, bowls, and equipment is essential.
• Isolation: New dogs entering a facility should be isolated for a period (e.g., 7 to 14 days) to monitor for signs of illness.
• Stress reduction: Stress suppresses the immune system and increases susceptibility to infection. Minimising stress in boarding and daycare settings is beneficial.
• Nutrition and general health: A balanced diet, regular exercise, and routine veterinary care support overall immune function.

Emergency Red Flags: When to Seek Veterinary Care

Most cases of kennel cough resolve without treatment within 7 to 14 days. However, owners should seek veterinary attention if their dog shows any of the following:

• Difficulty breathing or rapid breathing
• Blue or pale gums
• Lethargy or collapse
• Refusal to eat or drink for more than 24 hours
• High fever (above 39.5°C or 103°F)
• Cough that worsens or persists beyond 2 weeks
• Thick, coloured nasal discharge (yellow or green)
• Signs of pneumonia (e.g., crackling sounds when breathing, productive cough)

Puppies, senior dogs, and dogs with pre-existing health conditions are at higher risk for complications and should be evaluated early.

Clinical Reasoning Behind the Bordetella Vaccine Decision

The decision to administer the Bordetella vaccine is not a one-size-fits-all recommendation but rather a nuanced clinical judgment that balances individual patient risk, environmental factors, and the limitations of available immunologic tools. Veterinary clinicians must weigh the probability of exposure against the potential for adverse events and the realistic expectations of vaccine efficacy. This clinical reasoning process is essential because the Bordetella vaccine, unlike core vaccines, does not prevent a uniformly severe or life-threatening disease in every patient population.

The primary clinical consideration is the dog's lifestyle and social network. A dog that spends weekends at a busy urban dog park, attends weekly group training classes, and boards at a kennel twice yearly faces a fundamentally different risk profile than a dog that lives on a rural property with no contact with unfamiliar canines. The AAHA guidelines emphasize that the Bordetella vaccine is strongly recommended for socially active dogs, but the term "socially active" requires interpretation by the attending veterinarian [3]. A veterinarian must ask specific questions during the history-taking process: How often does the dog interact with dogs outside the household? Are those interactions in enclosed spaces or open areas? What is the respiratory disease prevalence in the local community? Does the dog have any underlying respiratory or cardiac conditions that could complicate a mild infection?

Another layer of clinical reasoning involves the timing of vaccination relative to planned social exposure. The intranasal vaccine's rapid onset of immunity within 3 to 5 days makes it a practical option for dogs with sudden boarding needs [3]. However, the injectable vaccine's slower onset requires advance planning. A veterinarian must also consider whether the dog has received prior Bordetella vaccinations or is immunologically naive. Naive dogs, particularly puppies, may require a booster series with the injectable formulation to achieve adequate protection, whereas previously vaccinated dogs may only need a single annual booster.

The clinical reasoning process also extends to multi-pet households. As noted in the ABCD guidelines, Bordetella bronchiseptica can infect cats, and dogs with respiratory disease pose a risk to feline housemates [2]. Therefore, a veterinarian may recommend Bordetella vaccination for a dog even if the dog itself is at low risk, if the household contains a cat that is young, old, or immunocompromised. This cross-species consideration adds a layer of complexity to the risk-benefit analysis that goes beyond the individual patient.

Diagnostic Workflow for Suspected Bordetella Infection

When a dog presents with clinical signs suggestive of CIRDC, the diagnostic workflow must be systematic and evidence-based. The classic presentation of Bordetella bronchiseptica infection includes a paroxysmal, honking cough that is often worse with excitement, exercise, or pressure on the trachea. Owners may report that the dog coughs as if something is stuck in its throat, and the cough may be followed by gagging or retching. However, these clinical signs are not pathognomonic for Bordetella, as viral pathogens such as canine parainfluenza virus and canine adenovirus type 2 can produce similar presentations.

The initial diagnostic step is a thorough history and physical examination. The veterinarian should inquire about recent exposure to other dogs, boarding history, vaccination status, and the duration and progression of clinical signs. On physical examination, the veterinarian may elicit a cough by gently palpating the trachea. Auscultation of the lungs may reveal normal breath sounds in uncomplicated cases or crackles and wheezes if pneumonia is present. The presence of fever, lethargy, or inappetence suggests a more severe infection that warrants further investigation.

For dogs with uncomplicated, mild clinical signs and a clear history of exposure, a presumptive diagnosis of CIRDC may be made without confirmatory testing. However, when diagnostic confirmation is needed, such as in outbreak investigations, shelter settings, or cases where treatment is not responding, specific testing is indicated. Bacterial culture of Bordetella bronchiseptica can be performed on samples obtained from the oropharynx, nasal passages, or transtracheal wash. However, culture sensitivity is limited, and false negatives can occur, particularly if the dog has already received antibiotics [2].

Polymerase chain reaction (PCR) testing offers higher sensitivity than culture and can detect Bordetella DNA from nasal or pharyngeal swabs [2]. PCR can also be incorporated into respiratory panels that test for multiple pathogens simultaneously, including canine parainfluenza virus, canine adenovirus type 2, canine influenza virus, and Mycoplasma species. This multiplex approach is particularly valuable in outbreak investigations or when a specific etiology must be identified for treatment or biosecurity purposes.

Thoracic radiography is indicated when pneumonia is suspected based on clinical signs such as fever, productive cough, dyspnea, or abnormal lung auscultation. Radiographic findings in Bordetella pneumonia may include alveolar or interstitial patterns, often in the right middle or cranial lung lobes. In severe cases, bronchopneumonia with consolidation may be evident.

Evidence Limitations in Bordetella Vaccine Research

Veterinary professionals and pet owners must understand the evidence limitations that surround the Bordetella vaccine. While the vaccine has been used for decades and is generally considered safe and effective, the quality of evidence supporting its use has important caveats.

First, much of the efficacy data for the Bordetella vaccine comes from challenge studies rather than large-scale field trials. Challenge studies involve vaccinating a group of dogs and then experimentally exposing them to Bordetella bronchiseptica under controlled conditions. While these studies demonstrate that the vaccine can reduce clinical signs and bacterial shedding, they may not fully replicate the complexity of natural exposure, where dogs encounter multiple pathogens simultaneously, variable infectious doses, and different strains of Bordetella bronchiseptica.

Second, the duration of immunity for the Bordetella vaccine is not as well-established as for core vaccines. The AAHA guidelines note that the intranasal vaccine provides protection for approximately 12 months, but some studies suggest that immunity may wane earlier, particularly in dogs with high exposure risk [3]. This uncertainty is why some boarding facilities require boosters every 6 months, especially during peak respiratory disease seasons. The lack of robust long-term immunity data means that veterinarians must make booster interval recommendations based on expert opinion and local practice patterns rather than definitive evidence.

Third, the vaccine's efficacy against different strains of Bordetella bronchiseptica is not fully characterized. While the vaccine contains antigens from commonly circulating strains, antigenic variation can occur, and breakthrough infections with heterologous strains have been reported. This is not unique to the Bordetella vaccine, it is a limitation shared with many bacterial vaccines, but it is an important consideration when setting owner expectations.

Fourth, the evidence base for the injectable vaccine's efficacy is less robust than for the intranasal formulation. The intranasal vaccine's ability to stimulate local mucosal immunity is theoretically superior for a pathogen that colonizes the respiratory epithelium, and clinical studies generally support this advantage. However, head-to-head comparisons of the two formulations in field settings are limited, and some dogs may still benefit from the injectable vaccine if the intranasal route is contraindicated or if the dog does not tolerate intranasal administration.

Finally, the evidence for the vaccine's ability to reduce transmission is limited. While vaccination reduces clinical signs and bacterial shedding, it does not eliminate shedding entirely. Vaccinated dogs can still become infected and transmit Bordetella bronchiseptica to other dogs, particularly if they are exposed to a high infectious dose. This has important implications for kennel and shelter settings, where vaccination should be viewed as one component of a comprehensive infection control program rather than a standalone solution.

Owner Observation and Preparation for a Veterinary Visit

Pet owners play a critical role in the early detection of respiratory disease and in preparing for a veterinary visit that will result in appropriate vaccination recommendations. Owners should be educated on what to observe and how to communicate effectively with their veterinarian.

Before a veterinary visit, owners should document their dog's social exposure history in detail. This includes not only boarding and daycare attendance but also less obvious exposures such as visits to dog-friendly cafes, participation in doggy playdates, walks in high-traffic urban areas, and interactions with neighbor's dogs. Owners should also note any recent changes in their dog's environment, such as the addition of a new pet to the household, a move to a new home, or travel to a different geographic region where respiratory disease prevalence may differ.

Owners should also observe and record any respiratory signs in their dog, even if mild. A single episode of coughing after drinking water may be insignificant, but a persistent cough that occurs multiple times per day warrants attention. Owners should note the character of the cough (honking, hacking, productive), its timing (worse at night, after exercise, or with excitement), and any associated signs such as nasal discharge, sneezing, lethargy, or decreased appetite. A video recording of the cough can be extremely helpful for the veterinarian, as owners may not be able to accurately describe the cough during the visit.

When preparing for a vaccination visit, owners should bring their dog's complete vaccination record, including the dates and types of all previous Bordetella vaccinations. This information helps the veterinarian determine whether the dog needs a booster or an initial series. Owners should also inform the veterinarian of any adverse reactions their dog has had to previous vaccinations, including mild signs such as facial swelling, hives, or vomiting, as well as more serious reactions such as anaphylaxis.

Owners should also be prepared to discuss their dog's overall health status. Dogs that are currently ill, have a fever, or are receiving immunosuppressive medications may need to delay vaccination. Pregnant dogs may have specific contraindications, particularly for the intranasal modified-live vaccine. A thorough discussion of the dog's medical history ensures that the vaccination decision is made with full knowledge of any potential risks.

Prevention Strategies Beyond Vaccination

While the Bordetella vaccine is a valuable preventive tool, it is most effective when integrated into a comprehensive respiratory disease prevention plan. This is particularly important in high-risk environments such as boarding kennels, daycare facilities, and shelters, where multiple dogs from different backgrounds are housed together.

Environmental management is a cornerstone of prevention. Bordetella bronchiseptica is susceptible to common disinfectants, including quaternary ammonium compounds, bleach solutions, and accelerated hydrogen peroxide products [2]. Surfaces, bowls, toys, and bedding should be cleaned and disinfected regularly, particularly in areas where dogs congregate. Kennels and daycare facilities should have protocols for cleaning between occupants and for deep cleaning during outbreaks.

Ventilation is another critical factor. Respiratory pathogens, including Bordetella bronchiseptica, can be aerosolized and transmitted through the air. Facilities should have adequate ventilation systems that provide fresh air exchange and reduce the concentration of airborne pathogens. In shelter settings, isolation rooms for sick animals should have separate ventilation systems to prevent pathogen spread to healthy animals.

Stress reduction is often overlooked but is essential for maintaining immune function. Dogs that are stressed, whether from boarding, travel, or social competition, have elevated cortisol levels that can suppress the immune system and increase susceptibility to infection. Facilities should provide comfortable, quiet spaces for dogs to rest, minimize overcrowding, and allow for gradual acclimation to new environments. Owners can also help by bringing familiar items such as bedding, toys, and food from home when boarding their dog.

Nutritional support and general health maintenance are also important. A balanced diet that meets the dog's nutritional needs supports immune function. Regular exercise, routine veterinary care, and parasite prevention all contribute to overall health and resilience against infection. Dogs with underlying health conditions such as chronic bronchitis, heart disease, or immunosuppression may be at higher risk for severe respiratory disease and may benefit from additional preventive measures.

Prognosis and Long-Term Considerations

The prognosis for dogs with uncomplicated Bordetella bronchiseptica infection is excellent. Most otherwise healthy adult dogs recover without specific treatment within 7 to 14 days. Supportive care, including rest, hydration, and nutritional support, is usually sufficient. However, the prognosis is less favorable for certain populations.

Puppies with immature immune systems are at higher risk for severe disease, including pneumonia. The StIKo Vet guidelines emphasize that basic immunisation in puppies is critical for long-term health, and this includes consideration of the Bordetella vaccine for puppies that will be socialized or boarded [1]. Puppies that develop Bordetella pneumonia may require hospitalization, intravenous fluids, oxygen therapy, and aggressive antibiotic treatment. The prognosis for puppies with pneumonia is guarded, and mortality can occur, particularly in very young or debilitated animals.

Senior dogs and dogs with pre-existing health conditions are also at increased risk for complications. Dogs with chronic bronchitis, tracheal collapse, or heart disease may experience exacerbation of their underlying condition during a respiratory infection. Dogs with immunosuppression, whether from disease or medication, may have difficulty clearing the infection and may develop chronic or recurrent disease.

Long-term considerations include the potential for chronic respiratory issues following severe infection. Dogs that have had Bordetella pneumonia may develop residual lung damage, including fibrosis or bronchiectasis, which can predispose them to future respiratory problems. Owners should be aware of this possibility and monitor their dog for any persistent respiratory signs after recovery.

For dogs that are at ongoing high risk of exposure, annual Bordetella vaccination is typically recommended. However, the decision to continue vaccination should be reassessed periodically based on the dog's changing lifestyle and risk profile. A dog that previously boarded frequently but now lives a more sedentary lifestyle may no longer need annual boosters. Conversely, a dog that previously had low exposure risk but now attends daycare may benefit from vaccination.

Special-Population Considerations

Certain populations of dogs require special consideration when it comes to Bordetella vaccination. These include brachycephalic breeds, dogs with respiratory or cardiac disease, dogs with a history of vaccine reactions, and dogs in shelter or rescue environments.

Brachycephalic breeds, such as Bulldogs, Pugs, and French Bulldogs, have anatomical abnormalities that predispose them to respiratory disease. Their shortened airways, elongated soft palates, and narrowed nostrils make them more susceptible to respiratory infections and more likely to develop severe complications. For these breeds, the decision to vaccinate should weigh the potential benefits of protection against the risks of vaccine-related respiratory signs. The intranasal vaccine may cause mild sneezing or nasal discharge, which can be more problematic in brachycephalic dogs with already compromised airways. However, the risk of severe Bordetella infection in these breeds may outweigh the vaccine risks, and many veterinarians recommend vaccination for brachycephalic dogs that have social exposure.

Dogs with pre-existing respiratory or cardiac disease require careful consideration. A dog with chronic bronchitis, tracheal collapse, or congestive heart failure may not tolerate even a mild respiratory infection. Vaccination may be recommended to reduce the risk of infection, but the veterinarian must also consider the potential for vaccine-related adverse effects. The injectable vaccine may be preferred in these cases to avoid the mild respiratory signs that can occur with the intranasal formulation.

Dogs with a history of vaccine reactions present a clinical challenge. Mild reactions such as facial swelling or hives can often be managed with pre-treatment antihistamines, and vaccination can proceed with caution. However, dogs with a history of anaphylaxis or other severe reactions should not be revaccinated unless the benefits clearly outweigh the risks, and then only under close veterinary supervision with emergency medications available.

Shelter and rescue environments present unique challenges for Bordetella vaccination. These facilities often have high dog turnover, limited resources, and high stress levels, all of which increase the risk of respiratory disease outbreaks. Many shelters vaccinate all incoming dogs against Bordetella as part of their intake protocol, regardless of the dog's individual risk profile. The intranasal vaccine is often preferred in shelter settings because of its rapid onset of immunity and its ability to stimulate local mucosal immunity [3]. However, shelters must also consider the logistics of administering the intranasal vaccine to large numbers of dogs and the potential for vaccine-related respiratory signs that could complicate the clinical picture in a population already at high risk for respiratory disease.

Frequently Asked Questions

1. Does my dog really need the Bordetella vaccine every year?

Not necessarily. The Bordetella vaccine is a noncore vaccine, meaning it is recommended based on your dog's risk of exposure. If your dog boards, attends daycare, visits groomers, or participates in group activities, annual boosters are typically recommended. For low-risk dogs, your veterinarian may advise less frequent vaccination or no vaccination at all.

2. Can the Bordetella vaccine give my dog kennel cough?

The intranasal modified-live vaccine can cause mild respiratory signs such as sneezing or a slight cough in some dogs. These signs are usually mild and self-limiting, lasting 1 to 3 days. They are not the same as full-blown kennel cough. The injectable vaccine does not cause respiratory signs.

3. How long before boarding should my dog get the Bordetella vaccine?

For the intranasal vaccine, protection begins within 3 to 5 days, but many boarding facilities require vaccination at least 7 to 14 days before check-in. For the injectable vaccine, allow 2 to 4 weeks. Always confirm the specific requirement with your boarding facility.

4. Will the Bordetella vaccine prevent all cases of kennel cough?

No. The Bordetella vaccine only protects against Bordetella bronchiseptica, which is one of many pathogens that cause kennel cough. Dogs can still contract respiratory infections from viruses such as canine parainfluenza, canine adenovirus type 2, canine influenza, and others.

5. Is there a difference between the intranasal and injectable Bordetella vaccine?

Yes. The intranasal vaccine stimulates local mucosal immunity and provides faster protection (3 to 5 days). The injectable vaccine provides systemic immunity but takes longer to become effective (2 to 4 weeks). The intranasal route is often preferred for dogs with high exposure risk.

6. Can my dog get the Bordetella vaccine at the same time as other vaccines?

Yes, the Bordetella vaccine can be given at the same visit as other vaccines. It is commonly administered alongside the core vaccines (distemper, parvovirus, adenovirus) and the rabies vaccine. Your veterinarian may administer them at different injection sites.

7. Are there any dogs that should not receive the Bordetella vaccine?

Dogs with a history of severe allergic reaction to a previous dose should not be revaccinated. Dogs that are ill or have a fever should wait until they recover. Pregnant dogs may be vaccinated with the injectable form in some cases, but the intranasal vaccine is not recommended during pregnancy. Always consult your veterinarian.

8. Does the Bordetella vaccine protect against canine influenza?

No. Canine influenza is caused by influenza A viruses (H3N8 and H3N2), which are completely different from Bordetella bronchiseptica. A separate canine influenza vaccine is available and is also considered noncore. Some dogs may benefit from both vaccines if they have high exposure risk.

Related Veterinary Guides

• Canine Distemper Vaccine: Core Protection for All Dogs
• Canine Parvovirus: Prevention and Vaccination Protocols
• Leptospirosis in Dogs: Zoonotic Risk and Vaccine Recommendations
• Canine Influenza Vaccine: What Dog Owners Need to Know
• Kennel Cough: Causes, Symptoms, and Treatment Options
• Puppy Vaccination Schedule: A Complete Guide for Owners
• Dog Boarding Health Requirements: What to Ask Your Kennel

Disclaimer: This article is educational and is not a substitute for veterinary diagnosis or treatment. Always consult a licensed veterinarian for medical advice specific to your dog's health.

References

[1] Arbeitskreis kleine Haustiere der Ständigen Impfkommission Veterinärmedizin (StIKo Vet). [Guidelines for the vaccination of small animals - 6th edition]. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2025. https://pubmed.ncbi.nlm.nih.gov/39965620/

[2] Egberink H, Addie D, Belák S et al. Bordetella bronchiseptica infection in cats. ABCD guidelines on prevention and management. J Feline Med Surg. 2009. https://pubmed.ncbi.nlm.nih.gov/19481041/

[3] AAHA: Key Vaccination, Bordetella, Canine Parainfluenza, and Canine Influenza. https://www.aaha.org/resources/2022-aaha-canine-vaccination-guidelines/bordetella-canine-parainfluenza-and-canine-influenza/

[4] AAHA: Canine Vaccination Guidelines Toolkit. https://www.aaha.org/resources/2022-aaha-canine-vaccination-guidelines/toolkit/

[5] AAHA: Recommendations for Core and Noncore Canine Vaccines. https://www.aaha.org/resources/2022-aaha-canine-vaccination-guidelines/recommendations-for-core-and-noncore-canine-vaccines/

[6] Ellis JA, Gow SP, Waldner CL et al. Comparative efficacy of intranasal and oral vaccines against Bordetella bronchiseptica in dogs. Vet J. 2016. https://pubmed.ncbi.nlm.nih.gov/27256028/

[7] Ellis JA, Gow SP, Waldner CL et al. Comparative efficacy of intranasal and injectable vaccines in stimulating Bordetella bronchiseptica-reactive anamnestic antibody responses in household dogs. Can Vet J. 2017. https://pubmed.ncbi.nlm.nih.gov/28761185/

[8] Hainer N, Velineni S, Bowers A et al. Oral vaccination of dogs with a monovalent live-avirulent vaccine confers one year of immunity against Bordetella bronchiseptica challenge. Vet J. 2021. https://pubmed.ncbi.nlm.nih.gov/34800656/

[9] Edinboro CH, Ward MP, Glickman LT. A placebo-controlled trial of two intranasal vaccines to prevent tracheobronchitis in dogs entering a humane shelter. Prev Vet Med. 2004. https://pubmed.ncbi.nlm.nih.gov/15156996/

[10] Wappel S, Velineni S, King V et al. Oral administration of a live-attenuated Bordetella bronchiseptica vaccine induces protective immunity seven days after vaccination in dogs. Am J Vet Res. 2026. https://pubmed.ncbi.nlm.nih.gov/42379217/